Salvage Therapy With High Dose Oral Clarithromycin in Relapsed or Refractory Extranodal Marginal Zone Lymphoma
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, phase II study on the activity and tolerability of high dose (2 g/day)
oral clarithromycin for the treatment of relapsed or refractory extranodal marginal zone
lymphoma.